Leqembi[®] (lecanemab) launched in China
Stockholm, Sweden, June 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi[®] (brand name in China: “乐意保[®]”, generic name: lecanemab) has been launched in China. Leqembi received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to launch Leqembi following the United States and Japan.Eisai estimates there are 17 million patients with MCI or mild dementia due to AD (collectively referred to as early AD) in China in 2024, which